Actively Recruiting
Drug Sensitivity of Hydrothorax and Ascite Organoids from Breast Cancer
Led by Second Affiliated Hospital, School of Medicine, Zhejiang University · Updated on 2025-01-07
90
Participants Needed
3
Research Sites
154 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Malignant hydrothorax and ascitic fluid in advanced breast cancer often arise from metastasis to the lungs, pleura, or liver. Patients with this condition experience rapid disease progression and multidrug resistance, facing limited treatment options. Clinical guidelines offer various therapies based on molecular subtypes; however, their effectiveness can be hindered by prior treatments, patient health, and tumor evolution. Current evaluations of treatment efficacy typically take two cycles, delaying the recognition of ineffective therapies and resulting in unnecessary side effects and costs. Organoid models present a promising solution, accurately replicating tumor structure and cellular diversity compared to traditional methods. These patient-derived models facilitate improved drug sensitivity testing, leading to more personalized treatment plans. In this study, 90 patients diagnosed with metastatic breast cancer accompanied by hydrothorax and ascitic fluid will be recruited. Patient-derived organoids will be used to assess the sensitivity of chemotherapy regimens, including Doxorubicin, Carboplatin, Cyclophosphamide, and Paclitaxel, along with targeted therapies such as Herceptin and Pertuzumab.
CONDITIONS
Official Title
Drug Sensitivity of Hydrothorax and Ascite Organoids from Breast Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed informed consent form and willingness to participate in the clinical study.
- Age between 18 and 70 years old.
- Confirmed metastatic breast cancer with hydrothorax and ascitic fluid containing tumor cells.
- ECOG performance status score of 0 or 1.
- No significant abnormalities in liver and kidney function (bilirubin <1.5 times upper limit of normal; ALT and AST <2.5 times upper limit of normal; creatinine ≤1 times upper limit of normal).
You will not qualify if you...
- Patients not suitable for chemotherapy and targeted therapy.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Second affiliated hospital of zhejiang university
Hangzhou, Zhejiang, China, 310000
Actively Recruiting
2
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China, 310000
Actively Recruiting
3
2 nd Affiliated Hospital, School of Medicine, Zhejiang University, China
Hangzhou, Zhejiang, China, 310009
Actively Recruiting
Research Team
Z
ZHIGANG CHEN, MD
CONTACT
J
JIAN HUANG, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here